Humoral and cellular immune memory to four COVID-19 vaccines.
COVID-19 vaccine
SARS-COV2
cellular immunity
humoral immunity
immune memory
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
07 07 2022
07 07 2022
Historique:
received:
18
03
2022
revised:
21
04
2022
accepted:
23
05
2022
pubmed:
29
6
2022
medline:
14
7
2022
entrez:
28
6
2022
Statut:
ppublish
Résumé
Multiple COVID-19 vaccines, representing diverse vaccine platforms, successfully protect against symptomatic COVID-19 cases and deaths. Head-to-head comparisons of T cell, B cell, and antibody responses to diverse vaccines in humans are likely to be informative for understanding protective immunity against COVID-19, with particular interest in immune memory. Here, SARS-CoV-2-spike-specific immune responses to Moderna mRNA-1273, Pfizer/BioNTech BNT162b2, Janssen Ad26.COV2.S, and Novavax NVX-CoV2373 were examined longitudinally for 6 months 100% of individuals made memory CD4
Identifiants
pubmed: 35764089
pii: S0092-8674(22)00653-5
doi: 10.1016/j.cell.2022.05.022
pmc: PMC9135677
pii:
doi:
Substances chimiques
Ad26COVS1
JT2NS6183B
Antibodies, Viral
0
COVID-19 Vaccines
0
NVX-CoV2373 adjuvated lipid nanoparticle
2SCD8Q63PF
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2434-2451.e17Subventions
Organisme : NIH HHS
ID : P40 OD012217
Pays : United States
Organisme : NIAID NIH HHS
ID : R25 AI147376
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA260541
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142742
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests A.S. is a consultant for Gritstone Bio, Flow Pharma, ImmunoScape, Avalia, Moderna, Fortress, Repertoire, Gerson Lehrman Group, RiverVest, MedaCorp, and Guggenheim. S.C. has consulted for GSK, JP Morgan, Citi, Morgan Stanley, Avalia NZ, Nutcracker Therapeutics, University of California, California State Universities, United Airlines, Adagio, and Roche. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. All other authors declare no conflict of interest.
Références
N Engl J Med. 2020 Oct 15;383(16):1544-1555
pubmed: 32722908
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-131
pubmed: 35085222
Nature. 2021 Dec;600(7889):517-522
pubmed: 34619745
Nature. 2022 Feb;602(7898):682-688
pubmed: 35016197
N Engl J Med. 2021 Dec 16;385(25):e90
pubmed: 34551224
J Immunol. 2015 Sep 1;195(5):1933-7
pubmed: 26297793
N Engl J Med. 2022 Feb 10;386(6):531-543
pubmed: 34910859
N Engl J Med. 2021 Sep 2;385(10):951-953
pubmed: 34260834
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Cell Host Microbe. 2021 Dec 8;29(12):1738-1743.e4
pubmed: 34861167
Nature. 2019 Jul;571(7763):122-126
pubmed: 31189952
Nat Rev Immunol. 2022 Mar;22(3):146
pubmed: 35169257
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Cell Rep Med. 2022 Feb 25;3(3):100562
pubmed: 35474748
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Sci Immunol. 2021 Dec 24;6(66):eabl5344
pubmed: 34726470
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Cell Rep Med. 2021 Jul 20;2(7):100355
pubmed: 34230917
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Sci Immunol. 2022 Mar 25;7(69):eabo2202
pubmed: 35113647
Nat Med. 2021 Dec;27(12):2127-2135
pubmed: 34650248
Cell. 2022 Apr 28;185(9):1588-1601.e14
pubmed: 35413241
JAMA. 2021 Oct 19;326(15):1533-1535
pubmed: 34459863
N Engl J Med. 2022 Mar 17;386(11):1088-1091
pubmed: 35081298
N Engl J Med. 2022 Mar 17;386(11):1046-1057
pubmed: 35081293
Cell. 2022 Mar 17;185(6):1008-1024.e15
pubmed: 35202565
Science. 2021 Oct 22;374(6566):eabj9853
pubmed: 34519540
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
N Engl J Med. 2021 Sep 23;385(13):1172-1183
pubmed: 34192426
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
Med. 2022 Feb 11;3(2):104-118.e4
pubmed: 35072129
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Nature. 2021 Dec;600(7890):580-583
pubmed: 34916666
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2021 Nov 18;385(21):2010-2012
pubmed: 34648703
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
Lancet. 2022 Feb 26;399(10327):814-823
pubmed: 35131043
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Immunity. 2010 Oct 29;33(4):451-63
pubmed: 21029957
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1337-1343
pubmed: 34555004
Nature. 2022 Mar;603(7901):493-496
pubmed: 35102312
Nat Rev Immunol. 2021 Feb;21(2):83-100
pubmed: 33353987
J Allergy Clin Immunol. 2022 Apr;149(4):1242-1252.e12
pubmed: 35093484
N Engl J Med. 2022 Mar 10;386(10):933-941
pubmed: 35020982
Nature. 2021 Apr;592(7853):283-289
pubmed: 33524990
Sci Immunol. 2021 Dec 10;6(66):eabj5129
pubmed: 34890255
J Infect Dis. 2022 Apr 1;225(7):1141-1150
pubmed: 34888672
Immunity. 2019 May 21;50(5):1132-1148
pubmed: 31117010
N Engl J Med. 2022 Jan 13;386(2):116-127
pubmed: 34942067
Nat Med. 2022 Mar;28(3):472-476
pubmed: 35042228
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
Cell. 2022 Feb 17;185(4):603-613.e15
pubmed: 35026152
Science. 2021 Sep 17;373(6561):1372-1377
pubmed: 34385356
Cell Host Microbe. 2021 Nov 10;29(11):1611-1619.e5
pubmed: 34688376